31
Participants
Start Date
November 10, 2021
Primary Completion Date
September 30, 2024
Study Completion Date
February 29, 2040
FT576 (Allogenic CAR NK cells with BCMA expression)
Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF).
Cyclophosphamide
Conditioning Agent
Fludarabine
Conditioning Agent
Daratumumab
Anti-CD38 Monoclonal Antibody
Bendamustine
Conditioning Agent
Roswell Park, Buffalo
Medical Oncology Hematology Consultants, Newark
Virginia Oncology Associates, Norfolk
Levine Cancer Institute, Charlotte
University of Alabama at Birmingham, Birmingham
Tennessee Oncology - Nashville, Nashville
Oncology Hematology Care, Inc, Cincinnati
Indiana University, Indianapolis
Medical College of Wisconsin, Milwaukee
University of Minnesota, Saint Paul
Washington University, St Louis
Texas Oncology-Medical City Dallas, Dallas
Scri-Cbci, Denver
City of Hope, Duarte
Lead Sponsor
Fate Therapeutics
INDUSTRY